Back
Madhya Pradesh High Court Grants under BNSS 2023 to Firm Proprietor and Medical Representative in Coldriff Cough Syrup Case
The has ordered the release of two individuals involved in the ongoing investigation regarding the distribution of "Coldriff" cough syrup—a case linked to serious allegations of chemical contamination. On , Justice Ajay Kumar Nirankari granted to Shailesh C. Pandiya, a firm proprietor, and Satish Verma, a medical representative, finding that the for continued detention had not been met.
Background of the Case The case stems from charges filed at in the Chhindwara District of Madhya Pradesh, involving alleged violations of the , and the . Both accused had been in since .
The investigation centers on the purity and safety of chemicals supplied for pharmaceutical use, specifically alleging the presence of diethylene glycol (DEG). The deaths associated with contaminated cough syrups have historically been a point of massive public health concern in the region, with previous court records noting severe impacts on child health in related incidents.
Arguments from the Defense The petitioners maintained their innocence while highlighting the specific nature of their involvement:
- Shailesh C. Pandiya: Represented by , Pandiya argued that he was merely a supplier of food-grade diethylene glycol. He contended that he was not the manufacturer of the chemical and had sourced it through legitimate trade channels, distancing himself from the claims that the article provided was substandard or intended for pharmaceutical misuse.
- Satish Verma: Represented by a team led by , the medical representative argued that he was an employee solely engaged in the sale of sealed, manufacturer-packaged syrup. He contended there was no evidence on record suggesting he possessed knowledge that the medicine was unsafe or manufactured in violation of established legal standards.
Legal Analysis and Observations The High Court’s decision to grant emphasized the distinction between manufacturers and secondary suppliers or distributors. In examining the case diary, the court drew a clear line regarding the substance supplied by Pandiya, noting its multi-purpose utility.
Justice Nirankari underscored that the process is not a but a determination of whether is necessary. By acknowledging that neither party was the primary manufacturer responsible for the formulation of the syrup, the court found the conditions ripe for temporary release on , subject to strict reporting requirements.
Key Observations The Court provided the following rationale for granting the relief:
"Having considered the facts that applicant is neither manufacturer neither article has been supplied is sub standard, this Court finds it fit to release the applicant on ."— Justice Ajay Kumar Nirankari regarding Shailesh C. Pandiya
"Having considered the facts and circumstances of the case, this Court finds it fit to release the applicant on ."— Justice Ajay Kumar Nirankari regarding Satish Verma
The Verdict and Implications The Court ordered the release of both applicants upon the furnishing of —Rs. 1,00,000 for Pandiya and Rs. 50,000 for Verma—alongside . The orders come with specific conditions, including regular attendance at the local police station and a strict prohibition against committing further offenses.
This decision reflects the judiciary's careful balancing of public safety against the rights of individuals accused of regulatory violations. While the trial continues, the release of these individuals signifies that, at least from a threshold perspective, the court found insufficient grounds for continued given the specific, arguably peripheral, roles assigned to these defendants compared to those involved in the core manufacturing chain. The case serves as a poignant reminder of the scrutiny applied to the pharmaceutical supply chain in India.
